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Objective: Behavioral-variant frontotemporal dementia (bvFTD) is a progressive neurodegenerative brain disorder,
clinically characterized by changes in cognition, personality, and behavior. Marked disturbances in eating behavior,
such as overeating and preference for sweet foods, are also commonly reported. The hypothalamus plays a critical
role in feeding regulation, yet the relation between pathology in this region and eating behavior in FTD is unknown.
This study aimed to address this issue using 2 complementary approaches.
Methods: First, 18 early stage bvFTD patients and 16 healthy controls underwent high-resolution structural magnetic
resonance imaging and assessment of eating behavior. Hypothalamic volumes were traced manually on coronal
images. Second, postmortem analyses of 12 bvFTD cases and 6 matched controls were performed. Fixed
hypothalamic tissue sections were stained for a cell marker and for peptides regulating feeding behaviors using
immunohistochemistry. Stereological estimates of the hypothalamic volume and the number of neurons and glia
were performed.
Results: Significant atrophy of the hypothalamus in bvFTD was present in both analyses. Patients with high feeding
disturbance exhibited significant atrophy of the posterior hypothalamus. Neuronal loss, which was observed only in
bvFTD cases with Tar DNA protein-43 deposition, was also predominant posteriorly. In contrast, orexin (hypocretin),
neuropeptide Y, cocaine- and amphetamine-regulating transcript, and vasopressin-containing neurons that regulate
appetite were spared in posterior nuclei known to participate in feeding regulation.
Interpretation: Degeneration and consequent dysregulation within the hypothalamus relates to significant feeding
disturbance in bvFTD. These findings provide a basis for the development of therapeutic models.
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F
rontotemporal dementia (FTD) is a progressive neu-
rodegenerative brain disorder. It is the second most
common cause of dementia and is as common as Alzhei-
mer disease in individuals with young onset dementia.
1
Three main clinical phenotypes of FTD are generally rec-
ognized based on clinical symptomatology at presenta-
tion: behavioral-variant FTD (bvFTD), semantic demen-
tia, and progressive nonfluent aphasia.
2 Each
presentation is characterized by a specific pattern of brain
atrophy that concentrates in the frontal and anterior tem-
poral lobes, although overlap occurs across presentation
with disease progression. Neuropathologically, most cases
of frontotemporal lobar degeneration (FTLD) show
intracytoplasmic protein deposition of either the microtu-
bule-associated phosphoprotein tau (FTLD-tau), or the
TAR-DNA–binding protein 43 (FTLD-TDP).
3–6 Clini-
cal presentation, however, remains an imperfect predictor
of underlying neuropathology.
The behavioral variant is the most common pheno-
type of FTD, accounting for >50% of all FTD cases. It
is characterized by changes in personal, social, and inter-
personal conduct, early emotional blunting, and loss of
insight.
2 Abnormal eating behaviors (eg, increased food
intake, changes in food preferences)
7 are present in
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312 V C 2011 American Neurological Association>60% of cases at presentation but affect >80% over the
course of the disease.
8 Weight gain is common, although
patients tend not to become morbidly obese, suggesting
changes in metabolism regulation. The biological causes
of feeding disturbance in FTD remain poorly
understood.
The hypothalamus plays a critical role in feeding
regulation.
9 This structure comprises a number of dis-
tinct but interconnected nuclei that directly receive and
integrate metabolic input from the periphery, as well as
indirect reward, motivation, and sensory input from the
cortex,
10 and then send signals to many regions of the
central nervous system regulating food intake and body
weight.
9,11 Two appetite-modulating pathways are pres-
ent: an appetite stimulating pathway, which starts with
an empty stomach secreting the hormone ghrelin to tar-
get neurons of the arcuate nucleus of the hypothalamus
that contain neuropeptide Y (NPY) and agouti-related
protein (AGRP), and an appetite-suppressing pathway
that starts with adipocytes secreting the hormone leptin
to target arcuate neurons containing pro-opiomelanocor-
tin and the cocaine- and amphetamine-regulated tran-
script (CART; Fig 1). Activation of these pathways
orchestrates a series of responses mediated by down-
stream centers including the paraventricular nucleus
(PVN) to control thyroid hormone secretion, feeding
behavior, and energy conservation, and by lateral hypo-
thalamic (LH) orexin-producing neurons to control
arousal responses and feeding behavior (see Fig 1).
12 The
hypothalamus in FTD has received only limited atten-
tion
13; its contribution to eating disturbance in FTD has
not been studied to date, and may have relevance for dis-
ease management. This study aimed to determine
changes in the hypothalamus in FTD by combining neu-
roimaging and postmortem investigations.
Subjects and Methods
Cohorts
Two separate cohorts of FTD patients were studied (recruit-
ment details and selection criteria are described in the Supple-
mentary Information) using methods approved by the Univer-
sity of New South Wales Human Ethics Committee. The
neuroimaging cohort comprised 18 patients who met clinical
diagnostic criteria for bvFTD
2 based on neurological and cogni-
tive examination at baseline, within 24 months of diagnosis.
Sixteen education-matched healthy controls were also enrolled.
The postmortem FTD cohort was selected at death for parallel
clinicopathological studies. It comprised 12 bvFTD, 6 with
FTLD-tau Pick body inclusions and 6 with FTLD-TDP
motoneuronlike inclusions (type 2)
14 without additional neuro-
pathologies, and 6 healthy controls free of significant neuropa-
thology (Table 1). In the neuroimaging cohort, patients with
bvFTD were significantly younger than the controls and
showed lower performance on cognitive tasks (Mini Mental
State Examination [MMSE] and Addenbrooke Cognitive Exam-
ination-Revised [ACE-R]) compared to controls. Sex distribu-
tion did not differ across groups, although females outnum-
bered males in the control group, and the reverse pattern was
found in the bvFTD. In the postmortem cohort, the bvFTD
and control groups were well matched for age, sex, and post-
mortem delay (see Table 1).
Characterization of Eating Behavior
Changes in eating behavior were established using the Cam-
bridge Behavioral Inventory (CBI)
15 in the neuroimaging
cohort. This carer questionnaire determines the presence and se-
verity (frequency) of a number of behavioral features using a 5-
point scale ranging from 0 (never) to 4 (constantly). A compos-
ite eating disturbance score was derived by summing the scores
from the relevant CBI items.
Neuroimaging and Region of Interest Analysis
All participants underwent a structural magnetic resonance
imaging (MRI) of the brain. A high-resolution (voxel size: 1  
1   1 mm) T1 image sequence was acquired to conduct mor-
phometric analyses of the hypothalamus. A second sequence
(dual T2 images) was collected to measure intracranial volume
to correct for interindividual head size differences (see Supple-
mentary Information for imaging sequence details). The hypo-
thalamus was traced manually on the T1 images in the coronal
plane using well-defined boundaries.
16 Given its structural com-
plexity and functional specificity, the obtained hypothalamic
volume was divided into 2 equal volumes in the anterior-
FIGURE 1: Diagrammatic representation of the appetite-
stimulating (green) and appetite-suppressing (red) pathways
between the periphery and the hypothalamus, and of their
connections within hypothalamic nuclei. PVN 5 paraventricular
nucleus; LHA 5 lateral hypothalamic area; DMN 5 dorsomedial
nucleus; DHA 5 dorsal hypothalamic area; VMN 5
ventromedial nucleus; NPY 5 neuropeptide Y; CART 5 cocaine-
and amphetamine-regulated transcript; ARC 5 arcuate nucleus.
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February 2011 313posterior axis (see Supplementary Information for detailed
description of the tracing protocol and Supplementary Fig 1).
Initial training was carried out on an independent set of 5
cases. High level of tracing reproducibility of the hypothalamus
volume was achieved (intraclass correlation ¼ 0.964). Anterior
and posterior hypothalamic volumes were expressed as a pro-
portion of intracranial volume to correct for individual and sex
differences in brain size.
Postmortem Tissue Preparation
Our previous studies have revealed no asymmetry in the cellular
components of the hypothalamus.
17,18 As such, coronal tissue
blocks of either the left or right hypothalamus were dissected
for each case for measurements. Absence of left/right hypothala-
mic asymmetry was confirmed in this sample for all volumetric
measurements and cellular counts (all p values > 0.30). Each
tissue block was cryoprotected in sucrose solution for 3 to 5
days before serially sectioning at 50lm on a cryostat. Every
15th section (750lm apart) was mounted onto gelatinized
slides and stained with 0.5% aqueous cresyl violet and 0.1%
Luxol fast blue for cellular quantitation and fiber tract recogni-
tion. Six other randomly selected series of sections were immu-
nohistochemically stained with antibodies against tau, TDP-43,
NPY, orexin, CART, and vasopressin (Supplementary Table).
Regional and Cellular Analysis
On each slide, the hypothalamus was traced manually using
similar regional boundaries defined in the neuroimaging proto-
col. Anterior and posterior regions were subdivided where the
paraventricular nucleus and the fornix were aligned horizontally.
The optical fractionator method was used to count neurons
with nucleoli and glial cells in the 50lm-thick Nissl-stained se-
rial sections.
19 All measurements were performed on blind-
coded slides.
Statistical Analyses
In the neuroimaging cohort, group differences between bvFTD
and healthy controls in hypothalamic volumes were investigated
using parametric independent sample t tests. Within the
bvFTD group, the relations between hypothalamic volumes and
eating disturbance were examined by contrasting hypothalamic
volumes in high and low scorers on the eating behavior com-
posite score, as the distribution of scores was bimodal. Informa-
tion on feeding was not available for 1 bvFTD patient. In the
postmortem cohort, given the small sample size, group differen-
ces were tested using nonparametric statistics: either Mann-
Whitney tests for 2 groups, or Kruskal-Wallis test for 3 groups
followed by post hoc Mann-Whitney tests to determine differ-
ences between subgroups.
Results
Eating Disturbances in FTD
Features of eating disturbance, such as increased appetite,
preference for sweet foods, and increased tendency to eat
the same foods, were present only in the bvFTD group
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314 Volume 69, No. 2and were not observed in the healthy controls (see Table
1). Within the bvFTD group, 10 patients, who displayed
the most frequent and severe features, were grouped into
a high eating disturbance group (defined by median
split). The 2 bvFTD subgroups did not differ with
respect to sex distribution, age, disease duration, or
MMSE or ACE-R scores.
Relations to Hypothalamic Changes In Vivo
Overall, bvFTD patients had smaller hypothalamic vol-
umes than controls (Fig 2), with atrophy most pro-
nounced posteriorly (reduced by 15%, p < 0.001) and
not significant anteriorly (p ¼ 0.08). Within the bvFTD
group, patients with a high eating disturbance score
exhibited greater posterior hypothalamic atrophy com-
pared with the other bvFTD patients (30% vs 10%
reduction in volume, t[16] ¼ 2.17, p ¼ 0.045; see Fig
2). Although the difference in sex distribution between
patient and control groups approached significance, no
statistical differences were found in the effect of sex on
hypothalamic volumes (all p values >0.10).
Pathological Changes in the Hypothalamus
in FTLD
Patients with FTLD-tau had more abnormal protein dep-
osition in the hypothalamus compared with patients with
FTLD-TDP. In FTLD-TDP, sparse TDP-immunoreac-
tive neurites were observed, with occasional intracytoplas-
mic inclusions in posterior hypothalamic neurons (inset
in Fig 3). In patients with FTLD-tau, tau-immunoreac-
tive neurons and neurites were observed throughout the
hypothalamus, with occasional Pick body inclusions (see
inset in Fig 3).
Comparison to In Vivo Changes and Assessment
of Centers Involved in Feeding Regulation
As found in vivo, postmortem bvFTD cases had signifi-
cant atrophy of the posterior (volume reduced by 35%;
U ¼ 8.0, z ¼  2.08, p ¼ 0.040; see Fig 2) but not the
anterior (U ¼ 9.0, z ¼  1.96, p ¼ 0.055) hypothalamus
compared to controls. Group analyses based on pathol-
ogy revealed that, despite a similar disease duration, the
volume loss arose from more severe atrophy in the
FTLD-TDP than in the FTLD-tau group compared to
controls (46% vs 22% reduction in volume; Table 2).
The severe posterior hypothalamic atrophy in the FTLD-
TDP group was associated with neuronal loss and sparse
pathology (see above). The low pathology burden in the
FTLD-TDP reflects the severity of the neuronal loss in
this group. No significant neuronal loss was present in
the FTLD-tau group compared with controls (U ¼ 4.0,
p ¼ 0.095). In contrast, the number of anterior hypo-
thalamic neurons and the total estimated number of glial
cells in the hypothalamus did not differ across groups.
Assessment of the centers involved in the regulation of
feeding (see Fig 1) revealed no obvious change in the
density or morphology of NPY- or CART-immunoreactive
neurons in arcuate nucleus in the anterior hypothalamus
(Fig 4). Surprisingly, substantive changes in the density or
morphology of orexin- and CART-immunoreactive neurons
in LH or other regions of the posterior hypothalamus, such
as the dorsomedial nucleus, were not found despite signifi-
cant loss of posterior hypothalamic neurons (see Fig 3).
FIGURE 2: Volumetric changes in the hypothalamus of
patients with behavioral-variant frontotemporal dementia
(bvFTD) compared to healthy controls. Volumes are
standardized to a percentage of the mean hypothalamic
volume of the healthy control group (the gray band
reflecting the standard deviation). (A) In vivo anterior and
posterior hypothalamic volumes in bvFTD corrected for
head size. Significant atrophy in the posterior hypothalamus
atrophy is observed in bvFTD at presentation. (B) In vivo
hypothalamic volumes in bvFTD patients exhibiting high or
low feeding disturbance corrected for head size. Greater
atrophy of the posterior hypothalamus (white bar, right) is
present in bvFTD patients with high feeding disturbances at
presentation compared to bvFTD patients with low feeding
disturbance and compared with healthy controls. (C)
Postmortem absolute anterior and posterior hypothalamic
volumes in frontotemporal lobar degeneration (FTLD).
Significant posterior hypothalamic atrophy in FTLD is
observed. (D) Postmortem absolute hypothalamic volumes
in FTLD patients exhibiting different inclusion pathologies.
More severe posterior hypothalamic atrophy is observed in
the FTLD-TDP group (white bar, right) compared with the
FTLD-tau group, and compared with healthy controls. MRI
5 magnetic resonance imaging; TDP-43 5 TAR-DNA–
binding protein 43. *Posterior hypothalamus in this group
is significantly smaller than that of healthy controls;
** posterior hypothalamus in this group is significantly
smaller than those of the other two groups.
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or morphology of vasopressin-immunoreactive neurons in
the PVN (see Fig 4).
Discussion
This study reveals a number of novel findings regarding
changes in hypothalamus integrity and its relations to
eating behavior in FTD. These results have important
clinical and theoretical implications and provide insight
into the explanation of a distressing feature of FTD that
has received surprisingly little attention. As hypothesized,
we demonstrated that patients with bvFTD exhibit sig-
nificant atrophy of the hypothalamus. Using structural
neuroimaging, we showed that this atrophy is an early
feature of the disease, being already present within 2
years of diagnosis. Our analyses further revealed that this
atrophy was most pronounced posteriorly, a region con-
taining nuclei that play a critical role in regulating feed-
ing behavior. In addition, atrophy in the posterior hypo-
thalamus was related to eating behavior in the bvFTD
group; patients with high feeding disturbance showed a
significantly smaller posterior hypothalamus compared to
those with less feeding problems. In contrast, the anterior
portion of the hypothalamus was not related to eating
behavior in this group. This finding has important impli-
cations, as it supports the view that atrophy of specific
nuclei in the hypothalamus contributes to the clinical
manifestation of feeding disturbance in bvFTD.
Previous structural neuroimaging studies have high-
lighted that disturbance in an orbitofrontal-insular-striatal
brain network underlies the emergence of eating disturb-
ance in FTD.
20–22 Surprisingly, the hypothalamus, which
plays a critical role in feeding regulation and regulates
other functions central for our metabolic needs (body
temperature, water balance, sleep cycle), has not been
implicated. Failure to detect changes in the hypothalamus
in previous studies was almost certainly methodological.
Here, we used region-of-interest identification with intra-
cranial correction, unlike previous works, which have
used voxel-based morphometry (VBM), an automated
method that investigates differences between groups at
the level of individual voxels. Although a powerful
approach to examine whole-brain effects without a priori
hypotheses, VBM is susceptible to artifacts, particularly
in populations with significant cortical atrophy, as is the
case with FTD, and has reduced power in detecting
changes in small brain structures.
23
Importantly, the presence of hypothalamic atrophy
in FTD was confirmed in a second cohort using a differ-
ent methodology. Postmortem tissue investigations
showed that the pattern of atrophy, with a more pro-
nounced change in the posterior than the anterior hypo-
thalamic region, was identical to that reported on MRI.
The severity of atrophy between the 2 studies differed,
however; atrophy in the postmortem cohort was at least
twice the magnitude of that found in the MRI cohort. In
the neuroimaging cohort, hypothalamic measurements
were obtained within 2 years of diagnosis, whereas meas-
urements on postmortem tissue were conducted after a
disease duration averaging 9 to 10 years. This finding
suggests that, although an early feature of the disease,
FIGURE 3: Comparisons of the posterior hypothalamic
regions (the dorsomedial [DM] and lateral hypothalamus
[LH] nuclei) involved in appetite stimulation between
controls and frontotemporal lobar degeneration (FTLD)
cases with tau or TAR-DNA–binding protein (TDP) pathology
reveals neuronal loss in FTLD-TDP compared to both
controls and FTLD-tau (row 1) in Nissl-stained sections
(0.5% aqueous cresyl violet [CV] and 0.1% Luxol fast blue
[LFB]). Insets illustrate tau (column 2) and TDP-43 (column 3)
immunopositive inclusion pathology observed in these
regions. Immunoperoxidase staining with cocaine- and
amphetamine-regulating transcript (CART, rows 2 and 4)
and orexin (rows 3 and 5) reveal no evident differences in
the density or morphology of neurons containing these
neuropeptides across groups in either the DM (rows 2 and
3) or the LH (rows 4 and 5).
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ing the course of the disease rather than being limited to
the initial phase of the illness. Interestingly, the site of
hypothalamic atrophy remains relatively consistent and
focused posteriorly over the disease course.
The inclusion pathologies underlying the clinical
presentation of bvFTD are variable and remain difficult
to predict in life, as clinical cases are evenly distributed
between tau- and TDP-positive inclusions.
24,25 Our post-
mortem analyses, however, demonstrated that hypothala-
mic atrophy was much more severe in cases with TDP-
positive inclusions compared to cases with tau-positive
inclusions. This atrophy was also accompanied by signifi-
cant neuronal loss in the TDP group only, and concen-
trated in nuclei known to regulate feeding behavior.
26,27
Additional evidence of selective changes in hypothalamic
feeding behavior in FTLD-TDP and not FTLD-tau
comes from a recent biomarker study showing increases
in cerebrospinal fluid AGRP only in FTLD-TDP cases.
28
Although information on eating behavior was not avail-
able in either postmortem cohorts, these results, together
with the neuroimaging findings, suggest that eating dis-
turbance in FTD is likely to reflect the presence of TDP
rather than tau pathology. Further studies are necessary
to confirm these findings.
Despite the considerable posterior cell loss in the
hypothalamus in the FTLD-TDP group, no apparent
loss of orexin- or CART-containing neurons was present
in nuclei that regulate feeding behavior. The loss of the
nonpeptidergic neurons in these posterior hypothalamic
nuclei may suggest a loss of internal inhibitory regulation
leading to overactivity of these peptidergic pathways and
the consequent feeding disturbances in bvFTD. Similar
disruption of the dorsomedial hypothalamic nucleus in
association with hyperactivity of the orexin neurons in
LH has been proposed to underlie the binge feeding in
attention-deficit/hyperactivity disorder.
29 The combina-
tion of pathology-specific neuronal loss together with the
preservation of neurons containing peptides involved in
feeding regulation may have considerable clinical implica-
tions as targeted therapeutic interventions are developed.
One of the strengths of this study is the combina-
tion of clinical information and in vivo imaging techni-
ques to measure changes in the hypothalamus plus post-
mortem confirmation of the findings in an independent
sample. The addition of a postmortem tissue arm to the
study allowed the investigation of specific neuron popu-
lations and peptides, which are too small to be detected
and measured with neuroimaging. The use of different
sample populations of clinically diagnosed patients and
neuropathologically confirmed cases is not ideal and
raises interesting questions regarding the underlying pa-
thology in the cases enrolled in the neuroimaging study.
The pathology study suggests that patients with TDP-43
inclusions may be particularly prone to eating disturb-
ance. Longitudinal investigations will be necessary to
obtain clinicopathological information on the same cases.
All neuroimaging cases were assessed by the same neurol-
ogist (J.R.H.), who has extensive experience in the early
clinical diagnosis of FTD. In addition, we were careful
in the FTD case selection to include only patients who
met current diagnostic criteria unequivocally, showed
clear cognitive deficits on neuropsychological examina-
tion, and exhibited cortical changes on MRI consistent
TABLE 2: Hypothalamic Volumes and Neuronal and Glial Counts in FTLD-TDP, FTLD-Tau, and Healthy Controls
(mean 6 standard deviation)
Hypothalamic Measures FTLD-TDP, n 5 6 FTLD-Tau, n 5 6 Controls, n 5 6 Group Differences
Volumes (mm
3)
Anterior 104 6 22 119 6 32 156 6 39 NS
Posterior 104 6 46 149 6 52 193 6 43
a
Neurons ( 10
3)
Anterior 608 6 229 1,002 6 421 1,142 6 355 NS
Posterior 786 6 400 1,251 6 453 1,307 6 362
ab
Glial cells ( 10
3)
Anterior 1,359 6 848 1,337 6 680 1,859 6 799 NS
Posterior 1,129 6 611 1,644 6 649 2,040 6 960 NS
abSignificant difference between FTLD-TDP and controls.
aSignificant difference between FTLD-TDP and FTLD-tau.
FTLD ¼ frontotemporal lobar degeneration; TDP ¼ TAR-DNA–binding protein; NS ¼ nonsignificant differences across groups.
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particularly important, reducing the likelihood of includ-
ing so-called phenocopy cases.
30 Longitudinal analyses
will also clarify the pattern of eating disturbance with
disease progression. Our postmortem analyses indicate
that atrophy of the hypothalamus is not confined to the
early phase of the illness, but is progressive over the
course of the disease. Clinically, however, little informa-
tion is available about changes in eating behavior over
time once the initial disturbance has been documented.
Importantly, disease progression in bvFTD is accompa-
nied by increasing apathy.
31 It is therefore plausible that
abnormal eating behavior may become less salient as apa-
thy becomes more prominent.
In conclusion, this study is the first to link atrophy
and pathology in the hypothalamus with eating disturb-
ance in bvFTD. Behaviorally, patients with a high level
of eating disturbance exhibited significant atrophy of the
posterior hypothalamus. Combined with the postmortem
investigations, our findings indicate that this eating dis-
turbance is related to neuronal loss in this region and is
greater in patients with TDP-43 pathology. A recent
study
28 supports the view that hypothalamic changes
appear specific to FTLD-TDP. Further studies are neces-
sary to clarify the contributions of other brain regions to
eating disturbance in FTLD. Overall, the present study
shows that degeneration and consequent dysregulation
within the hypothalamus relates to significant feeding
disturbance in bvFTD, providing a basis for the develop-
ment of therapeutic models for this clinical feature.
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